Silence Therapeutics PLC
Company Profile
Business description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Contact
72 Hammersmith Road
LondonW14 8TH
GBRT: +44 2034576900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
116
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,158.70 | 9.80 | 0.12% |
| CAC 40 | 8,042.95 | 51.25 | -0.63% |
| DAX 40 | 22,891.68 | 107.47 | -0.47% |
| Dow JONES (US) | 41,985.35 | 32.03 | 0.08% |
| FTSE 100 | 8,646.79 | 55.20 | -0.63% |
| HKSE | 23,689.72 | 530.23 | -2.19% |
| NASDAQ | 17,784.05 | 92.42 | 0.52% |
| Nikkei 225 | 37,677.06 | 74.82 | -0.20% |
| NZX 50 Index | 12,113.54 | 58.82 | 0.49% |
| S&P 500 | 5,667.56 | 4.67 | 0.08% |
| S&P/ASX 200 | 7,931.20 | 12.30 | 0.16% |
| SSE Composite Index | 3,364.83 | 44.12 | -1.29% |